Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Drew, Damien R ^a,b   Hodder, Anthony N ^b   Wilson, Danny W ^b   Foley, Michael ^c   Mueller, Ivo ^a,d   Siba, Peter M ^d   Dent, Arlene E ^e   Cowman, Alan F ^b   Beeson, James G ^a,b,f  

^a BURNET INSTITUTE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; APICAL MEMBRANE ANTIGEN 1; DNA; EPITOPE; MALARIA VACCINE;

ALLELE; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DNA SEQUENCE; GENETIC POLYMORPHISM; GROWTH INHIBITION; IMMUNOBLOTTING; MALARIA; MALARIA FALCIPARUM; MICROBIAL DIVERSITY; NONHUMAN; PHYLOGENY; PLASMODIUM FALCIPARUM; POLYACRYLAMIDE GEL ELECTROPHORESIS; RABBIT;

ALLELES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, PROTOZOAN; ANTIGENIC VARIATION; ANTIGENS, PROTOZOAN; BASE SEQUENCE; CROSS REACTIONS; HUMANS; MALARIA; MALARIA VACCINES; MEMBRANE PROTEINS; PARASITES; PHYLOGENY; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS;

PLASMODIUM FALCIPARUM;

EID: 84870781832     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051023     Document Type: Article

References (49)

1. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, et al. (2011) The threat of artemisinin-resistant malaria. N Engl J Med 365: 1073-1075.
2. Trape JF, Tall A, Diagne N, Ndiath O, Ly AB, et al. (2011) Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis 11: 925-932.
3. Remarque EJ, Faber BW, Kocken CH, Thomas AW, (2008) Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24: 74-84.
4. Anders RF, Adda CG, Foley M, Norton RS, (2010) Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum. Hum Vaccin 6: 39-53.
5. Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, et al. (2000) Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol 38: 706-718.
6. Hodder AN, Crewther PE, Anders RF, (2001) Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69: 3286-3294.
7. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, et al. (2002) In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70: 6948-6960.
8. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, et al. (2004) Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718-728.
9. Fowkes FJ, Richards JS, Simpson JA, Beeson JG, (2010) The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med 7: e1000218.
10. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, et al. (2009) Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 77: 1165-1174.
11. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, et al. (2002) Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 70: 6961-6967.
12. Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, et al. (1994) Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 51: 711-719.
13. Deans JA, Knight AM, Jean WC, Waters AP, Cohen S, et al. (1988) Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol 10: 535-552.
14. Anders RF, Crewther PE, Edwards S, Margetts M, Matthew ML, et al. (1998) Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16: 240-247.
15. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, et al. (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004-1013.
16. Chesne-Seck ML, Pizarro JC, Vulliez-Le Normand B, Collins CR, Blackman MJ, et al. (2005) Structural comparison of apical membrane antigen 1 orthologues and paralogues in apicomplexan parasites. Mol Biochem Parasitol 144: 55-67.
17. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, et al. (2009) Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 1: 2ra5.
18. Duan J, Mu J, Thera MA, Joy D, Kosakovsky Pond SL, et al. (2008) Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci U S A 105: 7857-7862.
19. Barry AE, Schultz L, Buckee CO, Reeder JC, (2009) Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS One 4: e8497.
20. Dutta S, Lee SY, Batchelor AH, Lanar DE, (2007) Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A 104: 12488-12493.
21. Healer J, Triglia T, Hodder AN, Gemmill AW, Cowman AF, (2005) Functional analysis of Plasmodium falciparum apical membrane antigen 1 utilizing interspecies domains. Infect Immun 73: 2444-2451.
22. Coley AM, Parisi K, Masciantonio R, Hoeck J, Casey JL, et al. (2006) The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect Immun 74: 2628-2636.
23. Beeson JG, Brown GV, Molyneux ME, Mhango C, Dzinjalamala F, et al. (1999) Plasmodium falciparum isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties. J Infect Dis 180: 464-472.
24. Fowler EV, Peters JM, Gatton ML, Chen N, Cheng Q, (2002) Genetic diversity of the DBLalpha region in Plasmodium falciparum var genes among Asia-Pacific isolates. Mol Biochem Parasitol 120: 117-126.
25. Miller LH, Roberts T, Shahabuddin M, McCutchan TF, (1993) Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol 59: 1-14.
26. Bhasin VK Trager W, (1984) Gametocyte-forming and non-gametocyte-forming clones of Plasmodium falciparum. Am J Trop Med Hyg 33: 534-537.
27. Triglia T, Duraisingh MT, Good RT, Cowman AF, (2005) Reticulocyte-binding protein homologue 1 is required for sialic acid-dependent invasion into human erythrocytes by Plasmodium falciparum. Mol Microbiol 55: 162-174.
28. Rayner JC, Tran TM, Corredor V, Huber CS, Barnwell JW, et al. (2005) Dramatic difference in diversity between Plasmodium falciparum and Plasmodium vivax reticulocyte binding-like genes. Am J Trop Med Hyg 72: 666-674.
29. Burkot TR, Williams JL, Schneider I, (1984) Identification of Plasmodium falciparum-infected mosquitoes by a double antibody enzyme-linked immunosorbent assay. Am J Trop Med Hyg 33: 783-788.
30. Hommel M, Elliott SR, Soma V, Kelly G, Fowkes FJ, et al. (2010) Evaluation of the antigenic diversity of placenta-binding Plasmodium falciparum variants and the antibody repertoire among pregnant women. Infect Immun 78: 1963-1978.
31. Elliott SR, Payne PD, Duffy MF, Byrne TJ, Tham WH, et al. (2007) Antibody recognition of heterologous variant surface antigens after a single Plasmodium falciparum infection in previously naive adults. Am J Trop Med Hyg 76: 860-864.
32. Thomas AW, Waters AP, Carr D, (1990) Analysis of variation in PF83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum. Mol Biochem Parasitol 42: 285-287.
33. Beeson JG, Mann EJ, Elliott SR, Lema VM, Tadesse E, et al. (2004) Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes and adhesion inhibitory antibodies are associated with placental malaria and have overlapping and distinct targets. J Infect Dis 189: 540-551.
34. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, et al. (2000) Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 44: 2100-2108.
35. Pearce JA, Triglia T, Hodder AN, Jackson DC, Cowman AF, et al. (2004) Plasmodium falciparum merozoite surface protein 6 is a dimorphic antigen. Infect Immun 72: 2321-2328.
36. Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, et al. (2007) The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg 76: 997-1008.
37. Persson KE, McCallum FJ, Reiling L, Lister NA, Stubbs J, et al. (2008) Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest 118: 342-351.
38. Persson KE, Lee CT, Marsh K, Beeson JG, (2006) Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol 44: 1665-1673.
39. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, et al. (2008) Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One 3: e3571.
40. Wilson DW, Crabb BS, Beeson JG, (2010) Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays. Malar J 9: 152.
41. Maier AG, Rug M, O'Neill MT, Brown M, Chakravorty S, et al. (2008) Exported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytes. Cell 134: 48-61.
42. Crabb BS, Triglia T, Waterkeyn JG, Cowman AF, (1997) Stable transgene expression in Plasmodium falciparum. Mol Biochem Parasitol 90: 131-144.
43. Harris KS, Casey JL, Coley AM, Masciantonio R, Sabo JK, et al. (2005) Binding hot spot for invasion inhibitory molecules on Plasmodium falciparum apical membrane antigen 1. Infect Immun 73: 6981-6989.
44. Polley SD, Chokejindachai W, Conway DJ, (2003) Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics 165: 555-561.
45. Kusi KA, Faber BW, Thomas AW, Remarque EJ, (2009) Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS One 4: e8110.
46. Kusi KA, Faber BW, Riasat V, Thomas AW, Kocken CH, et al. (2010) Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS One 5: e15391.
47. Dutta S, Dlugosz LS, Clayton JW, Pool CD, Haynes JD, et al. (2010) Alanine mutagenesis of the primary antigenic escape residue cluster, c1, of apical membrane antigen 1. Infect Immun 78: 661-671.
48. Remarque EJ, Faber BW, Kocken CH, Thomas AW, (2008) A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 76: 2660-2670.
49. Kusi KA, Remarque EJ, Riasat V, Walraven V, Thomas AW, et al. (2011) Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT and Montanide ISA 51 in rhesus macaques. Malar J 10: 182.